CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition Mittwoch, 24. Oktober 2018 - 06:56

Polyphor AG / Key word(s): Change of Personnel
CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition

24-Oct-2018 / 06:56 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Allschwil, Switzerland, October 24, 2018

CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition

Chief Medical and Development Officer Debra Barker has decided to leave
Polyphor at year end for personal reasons and will support on a part time
basis afterwards. Frank Weber, member of the Board, will further support the
company during the transition and assume ad interim the CMDO responsibility
from January 1st, 2019. A search for a replacement has been launched.

Polyphor announced today that Debra Barker, Chief Medical and Development
Officer, will leave the company at her own request to focus more on her
family and pursue part-time activity. She will continue to fully cover the
position until the end of the year and after that will support the company
on part-time basis to enable a smooth transition. Polyphor has initiated a
search for a successor CMDO to cover the position as soon as possible.
Additionally, Frank Weber, member of the Board and former Chief Medical
Officer at Merck-Serono will support the company on a part-time basis during
the transition period, and will assume ad interim the CMDO role from January
1st, 2019, until a new candidate will be retained.

"On behalf of the Board of Directors and executive team at Polyphor, I would
like to thank Debra for her leadership and support during this crucial
period of the company. She has been key in designing the murepavadin
PRISM-MDR and PRISM-UDR Phase III trials, in the advancement of the
balixafortide program and in supporting the IPO process, and wish her all
the best for her future" said Giacomo Di Nepi, Chief Executive Officer of
Polyphor.

About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company which has
discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead product, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical
priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology
candidate, balixafortide (POL6326), which is in preparation for a pivotal
trial program in combination with eribulin in patients with advanced breast
cancer, and a pipeline of further preclinical antibiotics based on its OMPTA
platform. Polyphor is based in Allschwil near Basel and is listed on the SIX
Swiss Exchange (SIX: POLN). For more information, please visit
www.polyphor.com.


For further information please contact:

For Investors:

Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com


For Media:

Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------